"The pivotal relation between glucagon-like peptides,NF κB and inflammatory bowel disease".

"The pivotal relation between glucagon-like peptides,NFκB and inflammatory bowel disease".
Clin Exp Pharmacol Physiol. 2020 Jun 08;:
Authors: Azmy Nabeh O, Attallah MI, El-Gawhary NE
Abstract
Glucagon-like peptides (GLPs); GLP-1 and GLP-2, are released from intestinal enteroendocrine (L cells) in response to ingested nutrients. GLP-1 plays a crucial role in lowering blood glucose and controlling body weight, through stimulating the islet ß cells of pancreas to secret insulin, inhibiting gastric emptying, and reducing food ingestion. Therefore, GLP-1 receptor agonists are now used in the treatment of obese patients with type 2 diabetes mellitus (T2DM). On the other hand, GLP-2 is used as a novel therapy for short bowel syndrome (SBS) through its ability to restore intestinal homeostasis and induce epithelial proliferation. GLPs and the inhibitors of their degradation enzymes, Dipeptidyl peptidase-IV (DPP-IV) inhibitors, have many anti-inflammatory actions. Many animal-based clinical trials have proved that GLPs based therapy has a pivotal role in the management of inflammatory bowel disease (IBD), possibly through regulating the transcription factor (NFκB). NFκB controls the production and secretion of many cytokines and chemokines encountered in the pathophysiology of IBD such as Interleukin (IL-1β-IL-12, IL-13, IL-21, IL-22, IL-6 and Tumor necrosis factor-alpha (TNF-α)) and hence, may provide a promising therapeutic option.
...

Source: Clinical and Experimental Pharmacology and Physiology - June 7, 2020 Category: Drugs & Pharmacology Authors: Azmy Nabeh O, Attallah MI, El-Gawhary NE Tags: Clin Exp Pharmacol Physiol Source Type: research